

TABLE OF CONTENTS

List of Figures	I
List of Tables	V
List of Materials and Reagents	VIII
List of Equipments	XI
List of Abbreviations	XIII
1 Introduction.....	1
1.1 Background.....	1
1.2 Objective of the proposed work.....	4
1.3 Hypothesis	4
1.4 Research design and Methods.....	5
1.5 Expected results	5
1.6 Work plan	5
1.7 References.....	7
2 Literature Review.....	9
2.1 Schizophrenia.....	9
2.1.1 Background	9
2.1.2 Pathophysiology.....	9
2.1.2.1 Neurotransmitter abnormalities	9
2.1.2.2 Anatomic abnormalities	10
2.1.2.3 Immune system and inflammation.....	10
2.1.3 Etiology	10
2.1.4 Epidemiology	11
2.1.5 Clinical presentation	11
2.1.6 Diagnosis.....	12
2.1.7 Treatment	13
2.1.7.1 Nonpharmacological therapy	13
2.1.7.2 Pharmacological therapy.....	13
2.1.8 Adverse effects.....	15
2.1.8.1 Endocrine system	15
2.1.8.2 Cardiovascular system	15
2.1.8.3 Lipid changes	16

2.1.8.4 Central nervous system	16
2.1.8.5 Miscellaneous	16
2.2 Gene therapy for schizophrenia	16
2.3 Neuregulin1 (NRG1)	18
2.3.1 NRG1 and schizophrenia	18
2.3.2 NRG1 signaling	18
2.3.3 NRG1 functions	19
2.4 RNA interference (RNAi).....	20
2.4.1 Background	20
2.4.2 Pathway	20
2.4.3 RNAi strategies	21
2.4.4 Clinical trials of RNAi therapeutics.....	22
2.4.5 Challenges for RNAi therapeutics	26
2.4.5.1 Intravascular degradation.....	26
2.4.5.2 Tissue penetrance and intracellular delivery.....	26
2.4.5.3 Intracellular trafficking	27
2.4.5.4 Extracellular factors	27
2.4.5.5 Immune mediated toxicities	27
2.4.5.6 Carrier mediated toxicities	28
2.4.5.7 Non-immune off target effects.....	28
2.4.5.8 Oversaturation of RISC.....	29
2.5 siRNA delivery	29
2.5.1 Cationic cell penetrating peptides (CPP)	30
2.5.2 Polymeric and dendrimeric carriers	30
2.5.3 siRNA bioconjugates	31
2.5.4 Lipid carriers	31
2.6 Barriers in the brain	31
2.6.1 Blood brain barrier	32
2.6.2 Blood cerebrospinal fluid barrier	33
2.6.3 Ependyma	33
2.7 Intranasal route for brain delivery	33
2.7.1 Nasal structure and physiology	33
2.7.2 Pathways and mechanism	34
2.7.2.1 Olfactory nerve pathway.....	34

2.7.2.2 Trigeminal nerve pathway	35
2.7.2.3 Vascular pathways	35
2.7.2.4 CSF pathway	35
2.7.2.5 Lymphatic pathway.....	36
2.7.3 Factors affecting nasal absorption and absorption enhancement.....	36
2.7.4 Formulations for nasal delivery	37
2.7.5 Advantages of nose to brain delivery.....	37
2.7.6 Disadvantages of nose to brain delivery	38
2.8 Patents on nose to brain delivery systems	38
2.9 References.....	40
3 Analytical Method Development.....	55
3.1 Selection of siRNA	55
3.2 UV spectrophotometric analysis	55
3.2.1 Preparation of siRNA stock solution	55
3.2.2 Determination of purity of siRNA sample	55
3.2.3 Quantification of siRNA	56
3.2.4 Accuracy and Precision.....	57
3.3 Agarose gel electrophoresis	58
3.3.1 Procedure	58
3.3.2 Determination of quantifiable range of siRNA for gel retardation assay ...	59
3.3.3 siRNA calibration curve.....	60
3.3.4 Accuracy and precision of method.....	61
3.4 References.....	64
4 Vector synthesis and characterization.....	65
4.1 Introduction.....	65
4.2 Synthesis method	66
4.2.1 bPEI-Hyaluronic acid (HA) copolymer	66
4.2.1.1 Background	66
4.2.1.2 Procedure	67
4.2.2 bPEI-lactoferrin (Lf) conjugate.....	67
4.2.2.1 Background	67
4.2.2.2 Procedure	68
4.2.3 bPEI-Chitosan (Chi) copolymer	68
4.2.3.1 Background.....	68

4.2.3.2 Procedure	69
4.2.4 Biodegradable bPEI	69
4.2.4.1 Background	69
4.2.4.2 Procedure	70
4.2.5 Biodegradable bPEI-Chitosan (Chi) copolymer	71
4.2.5.1 Procedure	71
4.2.6 Liposomes	71
4.2.6.1 Background	71
4.2.6.2 Procedure	72
4.3 Characterization	72
4.3.1 Nuclear magnetic resonance (NMR).....	72
4.3.2 Fourier transform – Infrared spectroscopy (FT-IR).....	72
4.3.3 Molecular weight determination	72
4.3.4 Muco-adhesion study	73
4.4 Result and discussion.....	73
4.4.1 Nuclear magnetic resonance (NMR).....	73
4.4.1.1 bPEI-HA copolymer	73
4.4.1.2 bPEI-Lf conjugate	75
4.4.1.3 bPEI-Chi copolymer	76
4.4.1.4 Biodegradable PEI	77
4.4.2 Fourier transform – Infrared spectroscopy (FT-IR).....	79
4.4.2.1 bPEI-HA copolymer	79
4.4.2.2 bPEI-Lf conjugate	81
4.4.2.3 bPEI-Chi copolymer	82
4.4.2.4 Biodegradable PEI	84
4.4.3 Molecular weight determination	85
4.4.4 Muco-adhesion study	90
4.5 References.....	91
5 Formulation development and characterization.....	97
5.1 Introduction.....	97
5.2 Procedure	98
5.2.1 Formulation of siRNA polyplexes	98
5.2.2 Formulation of lipopolyplexes	99
5.3 Characterization	99

5.3.1	Conjugation efficiency	99
5.3.2	Size distribution	100
5.3.3	Electrical surface charge or potential.....	100
5.3.4	Polyanion competition assay.....	100
5.3.5	Stability of formed colloidal nanocomplexes	101
5.3.6	Ex-vivo nasal permeation study.....	101
5.4	Result and discussion.....	101
5.4.1	Conjugation efficiency.....	101
5.4.2	Size distribution	104
5.4.3	Electrical surface charge or potential.....	108
5.4.4	Polyanion competition assay.....	113
5.4.5	Stability of formed colloidal nanoplexes	116
5.4.6	Ex-vivo nasal permeation study.....	117
5.4	References.....	121
6	In-vitro cell line studies	124
6.1	Introduction.....	124
6.2	SK-N-MC cell line.....	124
6.3	Subculturing/ passaging	125
6.3.1	Background	125
6.3.2	Protocol.....	125
6.4	Cell counting.....	126
6.4.1	Protocol.....	126
6.5	Cell cytotoxicity study	127
6.5.1	Background	127
6.5.2	Protocol.....	127
6.6	In-vitro permeation study.....	128
6.6.1	Background	128
6.6.2	Protocol.....	129
6.7	Cell uptake study	130
6.7.1	Confocal microscopy	130
6.7.1.1	Background.....	130
6.7.1.2	Protocol.....	131
6.7.2	Flow cytometry	131
6.7.2.1	Background.....	131

6.7.2.2 Protocol.....	132
6.8 Gene expression study	132
6.8.1 Background	132
6.8.2 Protocol	133
6.8.2.1 Cell culture.....	133
6.8.2.2 Selection of primers	133
6.8.2.3 RNA isolation	135
6.8.2.4 cDNA synthesis	135
6.8.2.5 mRNA quantification.....	136
6.9 Result and discussion.....	136
6.9.1 Cell cytotoxicity study	136
6.9.2 In-vitro permeation study.....	138
6.9.3 Cell uptake study.....	139
6.9.3.1 Confocal microscopy	139
6.9.3.1 Flow cytometry	140
6.9.4 Gene expression study	142
6.10 References.....	144
7 Formulation of nasal spray.....	148
7.1 Introduction.....	148
7.2 Procedure	151
7.3 Characterization	152
7.3.1 pH.....	152
7.3.2 Osmolality.....	152
7.3.3 Viscosity	152
7.3.4 Pump delivery volume	152
7.3.5 Priming.....	153
7.3.6 Repriming	153
7.3.7 Spray pattern	153
7.3.8 Plume geometry	153
7.3.9 Droplet size distribution.....	154
7.3.10 Weight loss.....	154
7.3.11 Tail-off characteristics	154
7.3.12 Microbial limit	154
7.3.13 Preservative efficacy study	155

7.4 Result and discussion.....	156
7.4.1 Physicochemical properties	156
7.4.2 Pump delivery volume	157
7.4.3 Priming.....	157
7.4.4 Repriming	162
7.4.5 Spray pattern	163
7.4.6 Plume geometry	164
7.4.7 Droplet size distribution.....	165
7.4.7.1 Effect of spraying angle on droplet size distribution.....	165
7.4.7.2 Effect of actuation force on droplet size distribution.....	167
7.4.7.3 Effect of actuation distance on droplet size distribution.....	168
7.4.7.4 Effect of hold time on droplet size distribution	169
7.4.8 Weight loss.....	172
7.4.9 Tail-off characteristics	173
7.4.10 Microbial limit test.....	175
7.4.11 Preservative efficacy study	176
7.5 References.....	177
8 In-vivo studies.....	179
8.1 Background.....	179
8.2 Selection of animals.....	180
8.3 Housing and feeding	180
8.4 Preparation of animals	180
8.5 Acute toxicity study	180
8.5.1 Preparation and administration of formulation	180
8.5.2 Main test.....	180
8.5.3 MTD determination	181
8.6 Nasal ciliotoxicity study	181
8.7 Brain distribution study	181
8.8 Efficacy study	182
8.8.1 Western blot.....	182
8.8.1.1 Preparation of lysate	182
8.8.1.2 Sample preparation	182
8.8.1.3 Loading and running gel	183
8.8.1.4 Transfer proteins on membrane	183

8.8.1.5 Antibody staining.....	184
8.8.2 Gene expression study	185
8.9 Result and discussion.....	185
8.9.1 Acute toxicity study	185
8.9.2 Nasal ciliotoxicity study	186
8.9.3 Brain distribution study.....	187
8.9.4 Efficacy study	188
8.9.4.1 Western blot.....	188
8.9.4.2 RT-PCR.....	189
8.10 References.....	191
9 Stability studies.....	193
9.1 Introduction.....	193
9.2 Procedure	194
9.2.1 Stability study of formulated polyplexes and lipopolyplexes.....	194
9.2.2 Stability study of nasal spray	194
9.3 Result and discussion.....	194
9.3.1 Stability of polyplexes and lipopolyplexes	194
9.3.2 Stability of nasal spray.....	195
9.4 References.....	198
10 Summary and conclusion.....	199